Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China

BackgroundThe 2021 Chinese Expert Consensus on the Clinical Application of the Human Papillomavirus (HPV) Vaccine recommended vaccination for women who previously received ablative or excisional treatment for high-grade squamous intraepithelial lesion (HSIL). This study evaluates the cost-effectiven...

Повний опис

Бібліографічні деталі

Автори:	Maosheng Zou, Hanting Liu, Huan Liu, Mengjie Wang, Zhuoru Zou, Lei Zhang
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2023-03-01
Серія:	Frontiers in Immunology
Предмети:	health economics (cost-effectiveness analysis) HPV vaccination cervical precancerous lesions women healthcare provider
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1119566/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!